Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of CST1 in prevention and/or treatment of liver immune disorder diseases

A technology for immune disorders and liver, applied in the field of biomedicine, can solve the problem of limited relief of acute liver failure

Active Publication Date: 2021-06-25
CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, mesenchymal stem cells (Mesenchymal Stem Cells, MSCs) transplantation in the treatment of acute liver failure has been proven to have a certain effect, but the study of the molecular mechanism of MSCs in the treatment of acute liver failure is still limited to the aspect of immune regulation, and it is found that the relevant immune regulatory factors are some known Factors that have modulatory effects on the immune system, and if used alone, have very limited therapeutic effect on acute liver failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CST1 in prevention and/or treatment of liver immune disorder diseases
  • Application of CST1 in prevention and/or treatment of liver immune disorder diseases
  • Application of CST1 in prevention and/or treatment of liver immune disorder diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0180] Example 1 Human endoderm stem cells (hEnSCs) for the treatment of acute liver failure and analysis of active ingredients

[0181] In order to find an alternative therapy for liver transplantation to treat acute liver failure, cell therapy is one of the potential therapies. Therefore, after trying a variety of potential cell types, we found a new type that is effective for acute liver failure. A stem cell line with good therapeutic effect, namely human endoderm stem cells (hEnSCs). Through animal experiments on rats with acute liver failure, we found that transplantation of hEnSCs through the hepatic portal vein can significantly improve the survival rate of animals within one week, and the effect is slightly better than that of mesenchymal stem cells known to have a certain effect on acute liver failure (MSCs)( figure 1 A). And the liver function indexes alanine aminotransferase (ALT), aspartate aminotransferase (AST) and blood ammonia (Blood Ammonia) were all signifi...

Embodiment 2

[0184] Example 2 Validation experiment of the curative effect of CST1 protein on acute liver failure

[0185] In order to verify what we think may be the key molecule for hEnSCs to treat acute liver failure, we decided to overexpress the CST1 gene in a cell line that does not express and has no therapeutic effect on acute liver failure, if the cell line can obtain a certain therapeutic effect on acute liver failure Therefore, it shows that the CST1 gene has a certain therapeutic effect on acute liver failure.

[0186] The cell line is human embryonic stem cells (ES), and then the lentivirus is used to package the CST1 overexpression plasmid vector and infect the ES to establish the ES cell line with CST1 overexpression, that is, CST1 + ES. Then detected whether the CST1 gene was overexpressed in the established cell lines, and compared its expression with hEnSCs, ES, MSC. like figure 2 A, CST1+ES overexpresses the CST1 gene, but the expression level is still lower than tha...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of CST1 in prevention and / or treatment of liver immune disorder diseases. Specifically, the invention provides an application of a CST1 gene, or a protein thereof or an accelerant thereof, the CST1 gene, or the protein thereof or the accelerant thereof is used for preparing a composition or a preparation, and the composition or the preparation is used for preventing and / or treating liver immune disorder diseases. The invention also accidentally finds that the CST1 protein and the CST1 overexpression-based cell therapy have great potential for the treatment of acute hepatic failure.

Description

technical field [0001] The present invention relates to the field of biomedicine, in particular, the present invention relates to the application of CST1 in the prevention and / or treatment of hepatic immune disorders. Background technique [0002] Acute liver failure (ALF) is an acute syndrome with high mortality, which is characterized by rapid necroptosis and apoptosis of a large number of hepatic parenchymal cells in a short period of time, and the loss of original liver function. And accompanied by intrahepatic immune system disorders, hepatic encephalopathy and possible multiple organ failure and other complications. [0003] The causes of acute liver failure include the following three types: those caused by hepatitis viruses such as hepatitis A, B and E (Hepatitis A, B&E); those caused by improper medication or poisoning, such as Chinese herbal medicine (Chinese Herbal Medicine), acetaminophen (Acetaminophen) ); other factors such as ischemic hepatocellular injury (I...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/57A61K45/00A61K45/06A61P1/16C12Q1/6883A61K35/545A61K35/28
CPCA61K38/57A61K45/00A61K45/06A61K35/545A61K35/28A61P1/16C12Q1/6883C12Q2600/136C12Q2600/158A61K2300/00G01N33/5073A61K48/00G01N2333/8139
Inventor 程新徐艺林
Owner CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com